Source: Globe Newswire
Journey Medical Corporation, a Fortress Biotech, Inc. (FBIO) company, launched Targadox™ (doxycycline hyclate USP) 50 mg film coated tablets indicated as adjunctive therapy for the treatment of severe acne. Targadox™ is the only 50 mg immediate-release doxycycline hyclate tablet currently available on the market. Targadox™ is available by prescription at major U.S. retail and specialty pharmacy chains. According to Symphony Health, doxycycline is the most-prescribed oral antibiotic in Dermatology with more than 3.7 million prescriptions written in 2015.
Acne is one of the most commonly treated disease states in dermatology. Doxycycline has both anti-inflammatory and antibacterial properties, two important characteristics for a medication in the treatment of acne. According to the American Academy of Dermatology 2016 “Guidelines of care for the management of acne vulgaris,” systemic antibiotics are recommended in the management of moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. Oral antibiotics should be used in combination with a topical retinoid and benzoyl peroxide.
Claude Maraoui, President and CEO of Journey Medical Corporation, said, “Launching four products in one year is a significant achievement for any size company. As a growing startup company, we credit the significant experience of our team and strategic allocation of resources for the achievement of this milestone. By targeting one of the most commonly treated diseases in dermatology, we expect Targadox™ will become our flagship brand in the near-term, as we continue to develop and commercialize dermatologic therapies for the future.”
Dr. Lindsay Rosenwald, Chairman and CEO of Fortress Biotech, said, “Journey Medical’s success in launching its fourth product this year is a testament to the leadership team’s expertise and dedication. As Fortress Biotech continues to implement its strategy of acquiring, developing and commercializing novel pharmaceutical and biotechnology products, Journey Medical exemplifies what we believe is a winning business model.”
About Journey Medical Corporation
Journey Medical Corporation (JMC), headquartered in Scottsdale, Arizona, is focused on developing, acquiring, licensing and commercializing branded dermatology products. It is a subsidiary of Fortress Biotech, Inc. For more information about Journey, visit www.jmcderm.com.
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress plans to develop and commercialize products both within Fortress and through subsidiary companies, also known as Fortress Companies. Fortress intends to leverage its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies achieve their goals. Additionally, Fortress intends to provide funding and management services to each of the Fortress Companies and, from time to time, Fortress and the Fortress Companies will seek licensing, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com.